This is a specific type of prolymphocytic leukemia that starts in B-cells. B-cells are a type of white blood cell that helps fight infection. This leukemia involves a large number of these B-cells in the blood and often causes the spleen to become very enlarged.
Every report comes from a Lived member, sent anonymously.
Have you tried Imbruvica (Ibrutinib) for B-Cell Prolymphocytic Leukemia?
B-cell prolymphocytic leukemia (B-PLL) is a very rare cancer of B lymphocytes, the white blood cells that make antibodies. In B-PLL, large abnormal cells called prolymphocytes build up in the blood, bone marrow and spleen. By definition, prolymphocytes make up more than 55% of the lymphocytes in the blood. It usually behaves more aggressively than chronic lymphocytic leukemia (CLL), the far more common B-cell leukemia it can resemble. Typical signs include a very high white blood cell count and a greatly enlarged spleen, which can cause fullness or discomfort under the left ribs. As the leukemia crowds the bone marrow, red blood cells and platelets can fall, leading to tiredness and easy bruising. Many people also have fever, drenching night sweats or unintended weight loss. Some people have no symptoms at first, and the leukemia is found on a routine blood test. B-PLL is a different disease from T-cell prolymphocytic leukemia, which affects another type of lymphocyte and is treated differently.
Doctors do not know what causes B-PLL, and no lifestyle habit or exposure has been shown to bring it on. It mainly affects older adults: the median age at diagnosis is in the early 70s, and men are diagnosed more often than women. The leukemia cells frequently carry changes in their genes and chromosomes, especially in MYC, a gene that drives cell growth, and in TP53, a gene that normally stops damaged cells from dividing. These changes do not explain why the disease started, but they matter because they help predict how it will behave and which treatments are likely to work.
B-PLL is usually first suspected from a complete blood count showing a very high lymphocyte count, often with anemia or low platelets. A specialist then examines a blood smear under the microscope and counts the prolymphocytes. Flow cytometry, a test that reads the protein markers on the surface of cells, confirms that the cells are abnormal B cells from a single clone. A bone marrow biopsy and imaging may show how far the disease has spread. The most important step is ruling out look-alikes. Mantle cell lymphoma, CLL and some lymphomas of the spleen can look very similar, and they are treated differently. Genetic tests on the leukemia cells, such as FISH (fluorescence in situ hybridization), look for the chromosome change typical of mantle cell lymphoma and for MYC and TP53 changes that guide treatment. The name itself is in flux. The World Health Organization's 2022 classification no longer lists B-PLL as a separate disease and sorts these cases into related diagnoses, such as a form of mantle cell lymphoma or a prolymphocytic progression of CLL. Another widely used system, the International Consensus Classification, still recognizes it. A pathology report may therefore use a different name for the same findings, and it is worth asking which one applies.
There is no treatment developed specifically for B-PLL, and no large clinical trials have compared options. Doctors usually adapt treatments proven in high-risk CLL, chosen according to symptoms, the genetic results, age and overall health. People who have no symptoms and stable blood counts may not need treatment right away. Instead, they have regular check-ups and blood tests, an approach called watch and wait. Treatment starts when symptoms, falling blood counts or a growing spleen appear. When treatment is needed, options include targeted drugs taken as pills, such as BTK (Bruton tyrosine kinase) inhibitors (ibrutinib, acalabrutinib or zanubrutinib), which block a signal B cells need to survive, and venetoclax, which removes a brake that keeps leukemia cells from dying. Small studies and case reports suggest these can work even when TP53 is abnormal. Chemoimmunotherapy, which pairs chemotherapy such as bendamustine with rituximab, an antibody that targets B cells, is another option. It tends to work poorly when TP53 is damaged, so genetic results strongly shape the choice. Responses to any of these treatments may not last, and many people need more than one line of treatment over time. For younger, fit people whose leukemia responds well, an allogeneic stem cell transplant (using cells from a donor) is the only treatment that may cure B-PLL. It involves high-dose treatment beforehand and carries serious, sometimes life-threatening complications, so it suits only a minority.
B-PLL is generally a serious, long-term illness, but its pace varies widely. In large records of people diagnosed in the United States between 2004 and 2019, half lived longer than about 3 years. Those who were well enough to start with watch and wait lived much longer, with a median of nearly 8 years. These figures describe groups, mostly from before targeted drugs were widely used, and cannot predict one person's course. Leukemias with both MYC and TP53 changes tend to progress fastest. For people without symptoms, follow-up means regular visits and blood tests. In one study, most people who started this way eventually needed treatment, often after several years. During treatment, visits are frequent to check blood counts, side effects and response. Tiredness and a higher risk of infection are common, both from the leukemia and from treatment. Because B-PLL is so rare, care is usually led by a hematologist (a blood cancer specialist), often with input from a center that sees many leukemia and lymphoma cases.
See a doctor if you have persistent tiredness, night sweats, unexplained weight loss or fullness under the left ribs, and ask whether a blood count is needed. If you are on watch and wait, tell your care team about these symptoms, swollen lymph nodes or new easy bruising, since they can signal that treatment should start. During treatment, or whenever your blood counts are low, call your care team right away for signs of infection, such as a fever of 100.5°F (38°C) or higher, chills, a cough or pain when urinating. Infections in this setting can become serious quickly. Ask before taking medicine to bring down a fever, because it can hide an infection.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with B-Cell Prolymphocytic Leukemia is like, what's helped you, or ask the community a question.